Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 21Melanoma 20Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 9Pancreatic Neoplasms 8Colorectal Neoplasms 8Rectal Neoplasms 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Colonic Neoplasms 3Thyroid Neoplasms 2Meningioma 2Leukemia, Myeloid, Acute 2Glioma 2Breast Neoplasms 2Brain Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma of Lung 2Thyroid Carcinoma, Anaplastic 1Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors, KRAS Mutation; SOS1 1Solid Tumors 1Solid Tumor Cancer 1Solid Tumor 1Sarcoma 1Rhabdoid Tumor 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Recurrence 1

Interventions

trametinib 1Radiotherapy 1Radiation 1GSK2141795 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Endometrial Adenocarcinoma × trametinib × Clear all
NCT01935973 2020-10-14

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡